Eunmi Choi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eunmi Choi has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Bonggi Kim
Korea Institute of Drug Safety and Risk Management, Anyang, Korea
2 shared publications - Ahyoung Suh
Office of Pharmacoepidemiology and Bigdata Analytics, Department of Drug Safety Information, Korea Institute of Drug Safety and Risk Management, Anyang-si, Republic of Korea
1 shared publication Eonji Na
Department of Drug Safety Information Korea Institute of Drug Safety and Risk Management Gyeonggi‐do Republic of Korea
1 shared publicationEunjun Park
Department of Drug Safety Information Korea Institute of Drug Safety and Risk Management Gyeonggi‐do Republic of Korea
1 shared publication- Hoon Jeong
Office of Pharmacoepidemiology and Bigdata Analytics, Department of Drug Safety Information, Korea Institute of Drug Safety and Risk Management, Anyang-si, Republic of Korea
1 shared publication Hyeri Yang
Department of Drug Safety Information Korea Institute of Drug Safety and Risk Management Gyeonggi‐do Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 8 November 2022
- Published by Springer Nature in Rheumatology International
- Vol. 43 (2) , 265-281
`Risk of cardiovascular disease associated with febuxostat versus allopurinol use in patients with gout: a retrospective cohort study in Korea
Febuxostat is the drug used to treat hyperuricemia in patients with gout. Recently, the usage of Febuxostat has been controversial over the side effects in cardiovascular. The study aimed to comparatively analyze the risk of cardiovascular disease associated with febuxostat and allopurinol use in Korean patients with gout. A cohort study was conducted using national insurance claim data from the Health Insurance Review and Assessment Service (HIRA). Adult patients who were diagnosed with gout and prescribed febuxostat or allopurinol more than once from July 1, 2015, to June 30, 2018 were studied. The outcome was cardiovascular disease. Analysis was performed using Cox’s proportional hazard model following 1:1 propensity score matching to estimate the hazard ratio with a 95% confidence interval. In total, 90,590 patients were defined as the final study cohort who had an average follow-up of 467 days, including 28,732 and 61,858 patients in the febuxostat and allopurinol groups, respectively. After the 1:1 propensity score matching, the risk of cardiovascular disease in the febuxostat group was significantly higher than in the allopurinol group (HR: 1.17; 95% CI: 1.10–1.24). In the sensitivity analysis, the risk of cardiovascular disease in the febuxostat group was significantly higher than in the allopurinol group (HR: 1.09; 95% CI: 1.04–1.15). However, further sensitivity analysis showed no statistically significant difference between the febuxostat group and allopurinol group after adjusting for cardiovascular disease history before the index date. Similarly, no statistically significant difference was found between the two drugs in the subgroup analysis. Febuxostat was not associated with a significantly increased risk of cardiovascular disease.
- 8 November 2022
- Published by Springer Nature in Rheumatology International
- Vol. 43 (2) , 265-281
Open Access`Risk of cardiovascular disease associated with febuxostat versus allopurinol use in patients with gout: a retrospective cohort study in Korea
Febuxostat is the drug used to treat hyperuricemia in patients with gout. Recently, the usage of Febuxostat has been controversial over the side effects in cardiovascular. The study aimed to comparatively analyze the risk of cardiovascular disease associated with febuxostat and allopurinol use in Korean patients with gout. A cohort study was conducted using national insurance claim data from the Health Insurance Review and Assessment Service (HIRA). Adult patients who were diagnosed with gout and prescribed febuxostat or allopurinol more than once from July 1, 2015, to June 30, 2018 were studied. The outcome was cardiovascular disease. Analysis was performed using Cox’s proportional hazard model following 1:1 propensity score matching to estimate the hazard ratio with a 95% confidence interval. In total, 90,590 patients were defined as the final study cohort who had an average follow-up of 467 days, including 28,732 and 61,858 patients in the febuxostat and allopurinol groups, respectively. After the 1:1 propensity score matching, the risk of cardiovascular disease in the febuxostat group was significantly higher than in the allopurinol group (HR: 1.17; 95% CI: 1.10–1.24). In the sensitivity analysis, the risk of cardiovascular disease in the febuxostat group was significantly higher than in the allopurinol group (HR: 1.09; 95% CI: 1.04–1.15). However, further sensitivity analysis showed no statistically significant difference between the febuxostat group and allopurinol group after adjusting for cardiovascular disease history before the index date. Similarly, no statistically significant difference was found between the two drugs in the subgroup analysis. Febuxostat was not associated with a significantly increased risk of cardiovascular disease.
- Open Access
- 10 January 2022
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 10 (1) , e00910
Risk of genital and urinary tract infections associated with SGLT‐2 inhibitors as an add‐on therapy to metformin in patients with type 2 diabetes mellitus: A retrospective cohort study in Korea
Sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors are antidiabetic drugs with associated safety concerns regarding the risk of genital and urinary tract infections. This study assessed the risk of genital and urinary tract infections associated with prescription of SGLT‐2 inhibitors as an add‐on therapy to metformin in patients with type 2 diabetes mellitus (T2DM) compared to dipeptidyl peptidase‐4 (DPP‐4) inhibitors, sulfonylurea (SU), and thiazolidinedione (TZD). We conducted a retrospective cohort study using the NHIS—National Health Insurance—Database in Korea from 2014 to 2017. Patients aged ≥19 years and those diagnosed with T2DM prior to drug prescription were enrolled. The outcomes were genital and urinary tract infections. Analysis was performed using Cox's proportional hazard model following 1:1 propensity score matching to calculate the hazard ratio (HR) with a 95% confidence interval (CI). Among the 107 131 patients included in the study, a total of 7738, 7145, and 2175 patients were assigned to the DPP‐4 inhibitors, SU, and TZD comparator groups, using the propensity score (PS) of each comparator based on 7741 people in the assessed drug SGLT‐2 inhibitor group. SGLT‐2 inhibitors were associated with a higher risk of genital infections than DPP‐4 inhibitors (HR: 2.39, 95% CI: 2.07–2.76), SU (HR: 3.23, 95% CI: 2.73–3.81), and TZD (HR: 3.23, 95% CI: 2.35–4.44), as an add‐on therapy to metformin. Similar results were observed for the risk of urinary tract infections. In conclusion, SGLT‐2 inhibitors are significantly associated with a higher risk of genital and urinary tract infections compared to DPP‐4 inhibitors, SU, and TZD.
- 10 January 2022
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 10 (1) , e00910
Open AccessRisk of genital and urinary tract infections associated with SGLT‐2 inhibitors as an add‐on therapy to metformin in patients with type 2 diabetes mellitus: A retrospective cohort study in Korea
Sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors are antidiabetic drugs with associated safety concerns regarding the risk of genital and urinary tract infections. This study assessed the risk of genital and urinary tract infections associated with prescription of SGLT‐2 inhibitors as an add‐on therapy to metformin in patients with type 2 diabetes mellitus (T2DM) compared to dipeptidyl peptidase‐4 (DPP‐4) inhibitors, sulfonylurea (SU), and thiazolidinedione (TZD). We conducted a retrospective cohort study using the NHIS—National Health Insurance—Database in Korea from 2014 to 2017. Patients aged ≥19 years and those diagnosed with T2DM prior to drug prescription were enrolled. The outcomes were genital and urinary tract infections. Analysis was performed using Cox's proportional hazard model following 1:1 propensity score matching to calculate the hazard ratio (HR) with a 95% confidence interval (CI). Among the 107 131 patients included in the study, a total of 7738, 7145, and 2175 patients were assigned to the DPP‐4 inhibitors, SU, and TZD comparator groups, using the propensity score (PS) of each comparator based on 7741 people in the assessed drug SGLT‐2 inhibitor group. SGLT‐2 inhibitors were associated with a higher risk of genital infections than DPP‐4 inhibitors (HR: 2.39, 95% CI: 2.07–2.76), SU (HR: 3.23, 95% CI: 2.73–3.81), and TZD (HR: 3.23, 95% CI: 2.35–4.44), as an add‐on therapy to metformin. Similar results were observed for the risk of urinary tract infections. In conclusion, SGLT‐2 inhibitors are significantly associated with a higher risk of genital and urinary tract infections compared to DPP‐4 inhibitors, SU, and TZD.